NASDAQ: VRCAVerrica Pharmaceuticals Inc Stock
$0.49+0.01 (+2.08%)
Updated Apr 17, 2025
VRCA Price
$0.49
Fair Value Price
-$0.46
Market Cap
$44.97M
52 Week Low
$0.38
52 Week High
$11.41
P/E
-0.33x
P/B
-4.56x
P/S
4.79x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.57M
Earnings
-$76.58M
Gross Margin
63.8%
Operating Margin
-887.75%
Profit Margin
-1,012.1%
Debt to Equity
-6.49
Operating Cash Flow
-$61M
Beta
0.95
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
VRCA Overview
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VRCA's potential to beat the market
- VRCA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
VRCA
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important VRCA news, forecast changes, insider trades & much more!
VRCA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VRCA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VRCA ($0.49) is overvalued by 206.85% relative to our estimate of its Fair Value price of -$0.46 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VRCA ($0.49) is not significantly undervalued (206.85%) relative to our estimate of its Fair Value price of -$0.46 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VRCA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VRCA due diligence checks available for Premium users.
Valuation
VRCA fair value
Fair Value of VRCA stock based on Discounted Cash Flow (DCF)
Price
$0.49
Fair Value
-$0.46
Undervalued by
206.85%
VRCA ($0.49) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VRCA ($0.49) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VRCA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VRCA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.33x
Industry
-177.72x
Market
27.98x
VRCA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-4.56x
Industry
4.05x
VRCA's financial health
Profit margin
Revenue
$344.0k
Net Income
-$16.2M
Profit Margin
-4,709.9%
VRCA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VRCA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$54.1M
Liabilities
$64.0M
Debt to equity
-6.49
VRCA's short-term assets ($51.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VRCA's short-term assets ($51.18M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VRCA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VRCA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.1M
Investing
$8.0k
Financing
$39.4M
VRCA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VRCA vs Biotech Stocks
Verrica Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.